Cargando…

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer

Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menke-van der Houven van Oordt, Catharina Willemien, Gootjes, Elske C., Huisman, Marc C., Vugts, Danielle J., Roth, Chantal, Luik, Anne Marije, Mulder, Emma R., Schuit, Robert C., Boellaard, Ronald, Hoekstra, Otto S., van Dongen, Guus AMS, Verheul, Henk M.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745807/ https://www.ncbi.nlm.nih.gov/pubmed/26309164

Ejemplares similares

Validation of simplified uptake measures against dynamic Patlak K(i) for quantification of lesional (89)Zr-Immuno-PET antibody uptake
por: Wijngaarden, Jessica E., et al.
Publicado: (2023)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2019)

(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018)

Optimal imaging time points considering accuracy and precision of Patlak linearization for (89)Zr-immuno-PET: a simulation study
por: Wijngaarden, Jessica E., et al.
Publicado: (2022)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body (18)F-Fluorodeoxyglucose and (89)Zr-Rituximab PET Scans
por: de Vries, Bart M., et al.
Publicado: (2022)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer
por: Bahce, Idris, et al.
Publicado: (2014)

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021)

Early (18)F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
por: van Helden, Erik J., et al.
Publicado: (2016)

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse
por: Bensch, Frederike, et al.
Publicado: (2018)

Performance of (89)Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
por: Jauw, Yvonne W. S., et al.
Publicado: (2017)

Feasibility of PET/CT system performance harmonisation for quantitative multicentre (89)Zr studies
por: Kaalep, Andres, et al.
Publicado: (2018)

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by (89)Zr-immuno-PET in xenograft bearing mice
por: Chomet, Marion, et al.
Publicado: (2020)

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach
por: Even, Aniek J.G., et al.
Publicado: (2016)

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study
por: Hagens, Marloes HJ, et al.
Publicado: (2017)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016)

Explainable artificial intelligence (XAI) in radiology and nuclear medicine: a literature review
por: de Vries, Bart M., et al.
Publicado: (2023)

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
por: van Helden, E. J., et al.
Publicado: (2018)

An automatic delineation method for bone marrow absorbed dose estimation in (89)Zr PET/CT studies
por: Makris, N.E., et al.
Publicado: (2016)

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
por: van Helden, Erik J., et al.
Publicado: (2019)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Diagnostic Performance of [(18)F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
por: Iqbal, Ramsha, et al.
Publicado: (2021)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Development of [(11)C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts
por: Slobbe, Paul, et al.
Publicado: (2017)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
por: Chomet, Marion, et al.
Publicado: (2020)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
por: Werter, Inge M., et al.
Publicado: (2022)

Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe
por: Heuveling, Derrek A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h39gvqkssievhg2702gr2itbl6